Methamphetamine and the risk of pulmonary arterial hypertension

Ramírez, Ramón Limón; Perez, Vinicio de Jesus; Zamanian, Roham T.

doi:10.1097/mcp.0000000000000513

Cited by 32 publications

(16 citation statements)

References 31 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7. COVID-19 itself has potential to increase overdose risk among people with SUD with chronic lung disease, previously identified as a risk factor for overdose mortality [16], and methamphetamine use may place people at increased risk of pulmonary hypertension [17], a risk factor for COVID-19 complications.…”

Section: Opioid Agonist Treatment (Oat) Should Bementioning

confidence: 99%

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic

et al. 2020

View full text Add to dashboard Cite

The impact of COVID-19 across health services, including treatment services for people who use drugs, is emerging but likely to have a high impact. Treatment services for people who use drugs provide essential treatment services including opiate agonist treatment and needle syringe programmes alongside other important treatment programmes across all substance types including withdrawal and counselling services. Drug and alcohol hospital consultation-liaison clinicians support emergency departments and other services provided in hospital settings in efficiently managing patients who use drugs and present with other health problems.COVID-19 will impact on staff availability for work due to illness. Patients may require home isolation and quarantine periods. Ensuring ongoing supply of opiate treatment during these periods will require significant changes to how treatment is provided. The use of monthly depot buprenorphine as well as moving from a framework of supervised dosing will be required for patients on sublingual buprenorphine and methadone. Ensuring ready access to take-home naloxone for patients is crucial to reduce overdose risks. Delivery of methadone and buprenorphine to the homes of people with confirmed COVID-19 infections is likely to need to occur to support home isolation.People who use drugs are likely to be more vulnerable during the COVID-19 epidemic, due to poorer health literacy and stigma and discrimination towards this group. People who use drugs may prioritise drug use above other health concerns. Adequate supply of clean injecting equipment is important to prevent outbreaks of blood-borne viruses. Opiate users may misinterpret SARS-CoV2 symptoms as opiate withdrawal and manage this by using opioids. Ensuring people who use drugs have access to drug treatment as well as access to screening and testing for SARS-CoV2 where this is indicated is important.

show abstract

Section: Opioid Agonist Treatment (Oat) Should Bementioning

confidence: 99%

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Those suffering from substance abuse and addiction represent a particularly vulnerable population during the COVID-19 crisis. Opiate dependence is known to be a risk factor for poor outcome with respiratory disease, whilst chronic methamphetamine use can led to pulmonary hypertension and heart failure, associated with worsened outcomes from COVID-19 [41,[81][82][83]. There is high collinearity between substance abuse and severe psychiatric disease, and those with either condition are more likely to experience homelessness or incarceration, which increases risk of poor COVID-19 outcomes [41].…”

Section: Psychiatry and Behavioural Medicinementioning

confidence: 99%

The impact of novel coronavirus COVID‐19 on noncommunicable disease patients and health systems: a review

et al. 2020

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) is an ongoing global pandemic affecting all levels of health systems. This includes the care of patients with noncommunicable diseases (NCDs) who bear a disproportionate burden of both COVID‐19 itself and the public health measures enacted to combat it. In this review, we summarize major COVID‐19‐related considerations for NCD patients and their care providers, focusing on cardiovascular, pulmonary, renal, haematologic, oncologic, traumatic, obstetric/gynaecologic, operative, psychiatric, rheumatologic/immunologic, neurologic, gastrointestinal, ophthalmologic and endocrine disorders. Additionally, we offer a general framework for categorizing the pandemic’s disruptions by disease‐specific factors, direct health system factors and indirect health system factors. We also provide references to major NCD medical specialty professional society statements and guidelines on COVID‐19. COVID‐19 and its control policies have already resulted in major disruptions to the screening, treatment and surveillance of NCD patients. In addition, it differentially impacts those with pre‐existing NCDs and may lead to de novo NCD sequelae. Likely, there will be long‐term effects from this pandemic that will continue to affect practitioners and patients in this field for years to come.

show abstract

“…Within the United States, it has been commonly accepted that methamphetamine use varies significantly by region, with higher rates of use in the West and Midwest ( 3 – 5 ). Potential explanations for this difference range from differences in drug manufacturing and distributing, with more direct drug trafficking through Mexico through the western half of the country, to higher rates of depression, suicide, and concomitant drug use at higher elevations ( 1 , 3 , 4 , 6 ).…”

mentioning

confidence: 99%

Regional Variation in Methamphetamine-associated Pulmonary Arterial Hypertension: Who’d Better Call Saul?

Prohaska

Machado

2021

Annals ATS

View full text Add to dashboard Cite

Methamphetamine and the risk of pulmonary arterial hypertension

Cited by 32 publications

References 31 publications

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic

The impact of novel coronavirus COVID‐19 on noncommunicable disease patients and health systems: a review

Regional Variation in Methamphetamine-associated Pulmonary Arterial Hypertension: Who’d Better Call Saul?

Contact Info

Product

Resources

About